Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules

Head and Neck

Volumn 33, Issue 1, 2011, Pages 95-97

  Giovanella, Luca ^a   Suriano, Sergio ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

calcitonin; heterophilic antibodies; medullary thyroid carcinoma

Indexed keywords

CALCITONIN; HETEROPHILE ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANTIBODY TITER; ARTICLE; CALCITONIN BLOOD LEVEL; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPURIOUS HYPERCALCITONINEMIA; THYROID NODULE;

ANTIBODIES, HETEROPHILE; BIOPSY, NEEDLE; CALCITONIN; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 78651374539     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21405     Document Type: Article

References (13)

1. Gacel RF, Hoff AO, Cote GJ,. Medullary thyroid carcinoma. Werner and Ingbar's The Thyroid, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. pp 967-988.
2. Elisei R,. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008; 22: 941-953.
3. d'Herbomez M, Caron P, Bauters C, et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007; 157: 749-755.
4. Papapetrou PD, Polymeris A, Karga H, Vaiopoulos G,. Heterophilic antibodies causing falsely high serum calcitonin values. J Endocrinol Invest 2006; 29: 919-923.
5. Kim JM, Chung KW, Kim SW, et al. Spurious hypercalcitoninemia in patients with nodular thyroid disease induced by heterophilic antibodies. Head Neck 2010; 32: 68-75.
6. Kricka LJ,. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45: 942-956.
7. Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12: 63-102.
8. Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK,. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009; 94: 861-868.
9. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK,. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003; 88: 3069-3074.
10. Giovanella L, Keller F, Ceriani L, Tozzoli R,. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2009; 47: 952-954.
11. Preissner CM, Dodge LA, O'Kane DJ, Singh RJ, Grebe SK,. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 2005; 51: 208-210.
12. Levinson SS, Miller JJ,. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002; 325: 1-15.
13. Bjerner J, Nustad K, Norum LF, Olsen KH, Børmer OP,. Immunometric assay interference: incidence and prevention. Clin Chem 2002; 48: 613-621.